Rankings
▼
Calendar
AMPH Q4 2023 Earnings — Amphastar Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
AMPH
Amphastar Pharmaceuticals, Inc.
$894M
Q4 2023 Earnings
Healthcare
Drug Manufacturers - Specialty & Generic
Income Statement
Revenue
$178M
+31.9% YoY
Gross Profit
$96M
54.0% margin
Operating Income
$54M
30.3% margin
Net Income
$36M
20.3% margin
EPS (Diluted)
$0.68
QoQ Revenue Growth
-1.4%
Cash Flow
Operating Cash Flow
$24M
Free Cash Flow
$14M
Stock-Based Comp.
$5M
Balance Sheet
Total Assets
$1.5B
Total Liabilities
$873M
Stockholders' Equity
$639M
Cash & Equivalents
$144M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$178M
$135M
+31.9%
Gross Profit
$96M
$71M
+35.1%
Operating Income
$54M
$38M
+42.7%
Net Income
$36M
$34M
+6.6%
Revenue Segments
Product revenues, net
$441M
95%
Other revenues
$22M
5%
Geographic Segments
UNITED STATES
$175M
98%
CHINA
$2M
1%
FRANCE
$459,000
0%
← FY 2023
All Quarters
Q1 2024 →